Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25°C

American Journal of Health-System Pharmacy

Volumn 67, Issue 14, 2010, Pages 1191-1194

  He, Jie ^a   Figueroa, Deborah A ^b   Lim, Tze Peng ^c   Chow, Diana S ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b NEW YORK HOSPITAL QUEENS   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Antibiotics; Concentration; Diluents; Injections; Kinetics; Polymyxin B sulfate; Refrigeration; Sodium chloride; Stability; Storage; Temperature

Indexed keywords

POLYMYXIN B; SODIUM CHLORIDE; STERILE WATER; ANTIINFECTIVE AGENT; EXCIPIENT;

ARTICLE; BORDETELLA BRONCHISEPTICA; DRUG DECOMPOSITION; DRUG MANUFACTURE; DRUG QUALITY; DRUG STABILITY; DRUG STORAGE; FREEZING; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE; STORAGE TEMPERATURE; CHEMISTRY; DRUG CONTAMINATION; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; KINETICS; SOLUTION AND SOLUBILITY; TEMPERATURE; TIME;

ANTI-BACTERIAL AGENTS; BORDETELLA BRONCHISEPTICA; DRUG CONTAMINATION; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; INFUSIONS, INTRAVENOUS; KINETICS; PHARMACEUTICAL SOLUTIONS; POLYMYXIN B; REFRIGERATION; SODIUM CHLORIDE; TEMPERATURE; TIME FACTORS;

EID: 77957668945     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090472     Document Type: Article

References (13)

1. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40:1333-41. (Pubitemid 40570245)
2. Lee SY, Kuti JL, Nicolau DP et al. Polymyxins: older antibiotics for a new threat. Conn Med. 2006; 70:25-8. (Pubitemid 43062683)
3. Rice LB. Emergence issues in the management of infections caused by multidrugresistant gram-negative bacteria. Cleve Clin J Med. 2007; 74:S12-20.
4. Holloway KP, Rouphael NG, Wells JB et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother. 2006; 40:1939-45. (Pubitemid 44747462)
5. Furtado GH, d'Azevedo PA, Santos AF et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007; 30:315-9. (Pubitemid 47361713)
6. Orwa JA, Govaerts C, Gevers E et al. Study of the stability of polymyxins B1, E1 and E2 in aqueous solution using liquid chromatography and mass spectrometry. J Pharm Biomed Anal. 2002; 29:203-12. (Pubitemid 34621282)
7. Polymyxin B for injection package insert. Northport, NY: XGEN Pharmaceuticals; 2006 May.
8. Polymyxin B for injection package insert. Schaumburg, IL: APP Pharmaceuticals LLC; 2008 Nov.
9. Antibiotics - microbial assays (chapter 81). In: The United States pharmacopeia, 30th rev., and The national formulary, 25th ed. Rockville, MD: United States Pharmacopeial Convention; 2007:103-5.
10. Orwa JA, Govaerts C, Busson E et al. Isolation and structural characterization of polymyxin B components. J Chromatogr A. 2001; 912:369-73. (Pubitemid 32234375)
11. Polymyxin B for injection (monograph). In: The United States pharmacopeia, 30th rev., and The national formulary, 25th ed. Rockville, MD: United States Pharmacopeial Convention; 2007:2968.
12. Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008; 17:661-8. (Pubitemid 351843610)
13. Dextrose injection (monograph). In: The United States pharmacopeia, 30th rev., and The national formulary, 25th ed. Rockville, MD: United States Pharmacopeial Convention; 2007:1906.